Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles. Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. Gilead and Merck will share global development and commercialization costs 60% and 40%, respectively, while having an equal share of the therapy's sales until the revenue crosses certain milestones. GSK has been in conversations with the U.S. government and is working through existing commercial channels to make sotrovimab available to patients and health systems in need, Kathleen Quinn, a company spokeswoman, said.
Gilead -  stands to benefit the poor.
( z0 stand :ARG0 ( z1 person :name ( z2 name :op "Gilead" ) ) :ARG1 ( z3 benefit :ARG0 z1 :ARG1 ( z4 person :mod ( z5 poor ) ) ) )
(z0 / stand-08
    :ARG0 (z1 / person
              :name (z2 / name
                        :op1 "Gilead"))
    :ARG1 (z3 / benefit-01
              :ARG0 z1
              :ARG1 (z4 / person
                        :mod (z5 / poor))))
Gilead - stands to benefit the poor .
z1 :name z2
z2 :op1 0
z0 :ARG0 z1
z0 :ARG1 z3
z3 :ARG0 z1
z3 :ARG1 z4
z4 :mod z5